SMAD4 and hereditary hemorrhagic telangiectasia: Because patients with pathogenic SMAD4 variants commonly have one or more features of hereditary hemorrhagic telangiectasia (HHT), these patients may potentially increase their risk for developing severe aortic symptoms when taking fluoroquinolones.